US2021093614A1PendingUtilityA1

Mazindol combination in the treatment of attention-deficit/hyperactivity

63
Assignee: NLS PHARMACEUTICS AGPriority: Apr 11, 2006Filed: Oct 9, 2020Published: Apr 1, 2021
Est. expiryApr 11, 2026(expired)· nominal 20-yr term from priority
Inventors:Eric Konofal
A61K 33/26A61K 31/4188A61P 25/26A61P 25/00A61P 25/18A61K 45/06A61P 25/20A61K 31/4184A61K 31/555A61P 25/16A61K 31/41A61P 25/28A61P 43/00A61K 9/0053
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A pharmaceutical composition consisting essentially of a pharmaceutically acceptable excipient and mazindol in an amount effective to treat ADHD.

Join the waitlist — get patent alerts

Track US2021093614A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.